# TQB2922

Source: https://onco.cc/drugs/tqb2922/  
OnCo record `tqb2922` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TQB2922 is an experimental bispecific antibody from Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical in phase 2 trials for colorectal cancer, aimed at EGFR and MET.

## Summary

TQB2922 is a bispecific antibody developed by Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical. Its targets are EGFR and MET (the sponsor names EGFR x c-Met). The sponsor states: TQB2922 is an anti-EGFR/c-Met bispecific IgG1 antibody that blocks EGFR and c-Met signalling by binding both receptors on tumour cells and engages antibody-dependent cellular cytotoxicity and phagocytosis via NK cells and macrophages. ClinicalTrials.gov describes the intervention as: TQB2922 is an anti-EGFR/c-Met bispecific antibody, subtype Immunoglobulin G1 (IgG1). TQB2922 blocks the activation of EGFR and c-Met signalling pathway by binding to EGFR and c-Met on the surface of tumour cells, thus preventing tumour grow. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in colorectal cancer. The largest, NCT07044908, plans to enrol 72 participants with primary completion was scheduled for 2026-07 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: bispecific antibody
- Mechanism: TQB2922 is an anti-EGFR/c-Met bispecific IgG1 antibody that blocks EGFR and c-Met signalling by binding both receptors on tumour cells and engages antibody-dependent cellular cytotoxicity and phagocytosis via NK cells and macrophages.

## Sources

- ClinicalTrials.gov: trials of TQB2922: https://clinicaltrials.gov/search?intr=TQB2922

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- targets: [EGFR](https://onco.cc/targets/egfr/), [MET](https://onco.cc/targets/met/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)
- trials: [TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer](https://onco.cc/trials/nct07044908/)

---
JSON: https://onco.cc/api/v1/entities/tqb2922.json